Am J Perinatol 2020; 37(04): 415-420
DOI: 10.1055/s-0039-1679917
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Use of Point-of-Care Gastric pH Testing to Assess the Efficacy of Acid Suppression Therapy in the Neonatal Intensive Care Unit

Osayame A. Ekhaguere
1   Division of Neonatology, Department of Pediatrics, Riley Children's Hospital, Indiana University, Indianapolis, Indiana
,
Michael A. Padula
2   Division of Neonatology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania
,
Erik A. Jensen
2   Division of Neonatology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania
› Author Affiliations
Further Information

Publication History

02 August 2018

22 January 2019

Publication Date:
19 February 2019 (online)

Abstract

Objective The use of acid suppression therapies in newborns lacks efficacy and is associated with adverse effects. Point-of-care (POC) assessment of gastric aspirate pH may provide an objective, noninvasive measure of gastric acidity in tube fed infants. We conducted the present study to characterize the POC gastric pH levels in gastric tube fed infants before and after initiation of enteral omeprazole or ranitidine.

Study Design Retrospective cohort study of infants with gastric aspirate pH levels determined by POC pH strips. Gastric pH levels recorded during 7 days before and 14 days after medication initiation were compared using Wilcoxon's sign-rank tests.

Results Among 307 evaluated infants, 284 (92%) had a median gastric pH level ≥4 in 7 days prior to ranitidine or omeprazole. In 14 days after medication initiation, the median gastric pH of infants with pretreatment median gastric pH < 4 increased to 4.5 and 5 (p < 0.01) in the ranitidine and omeprazole groups, respectively. There was no change in infants with pretreatment median gastric pH ≥4.

Conclusion Among infants receiving gastric tube feedings and enteral omeprazole or ranitidine, only those with a pretreatment gastric pH level <4 demonstrated a significant increase in gastric pH. Validation of our findings against esophageal pH multichannel intraluminal impedance testing is needed.

 
  • References

  • 1 Eichenwald EC. ; Committee On Fetus And Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants. Pediatrics 2018; 142 (01) e20181061
  • 2 Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States Children's Hospitals. J Pediatr 2016; 174: 63-70
  • 3 van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011; 127 (05) 925-935
  • 4 Guillet R, Stoll BJ, Cotten CM. , et al; National Institute of Child Health and Human Development Neonatal Research Network. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117 (02) e137-e142
  • 5 Patole S. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis: a case of excessive collateral damage?. Pediatrics 2006; 117 (02) 531-532
  • 6 Terrin G, Passariello A, De Curtis M. , et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012; 129 (01) e40-e45
  • 7 Rosen R. Gastroesophageal reflux in infants: more than just a pHenomenon. JAMA Pediatr 2014; 168 (01) 83-89
  • 8 Dias FD, Emidio SC, Lopes MH, Shimo AK, Beck AR, Carmona EV. Procedures for measuring and verifying gastric tube placement in newborns: an integrative review. Latin-American Journal of Nursing 2017; 25: e2908
  • 9 Reducing the harm caused by misplaced nasogastric feeding tubes in adults, children and infants Available at: http://www.nrls.npsa.nhs.uk/alerts/?entryid45=129640 . Accessed November 9, 2017
  • 10 Vandenplas Y, Rudolph CD, Di Lorenzo C. , et al; North American Society for Pediatric Gastroenterology Hepatology and Nutrition; European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49 (04) 498-547
  • 11 Fleiss JL. Design and Analysis of Clinical Experiments. Hoboken, New Jersey: John Wiley & Sons; 2011
  • 12 Omari TI, Barnett CP, Benninga MA. , et al. Mechanisms of gastro-oesophageal reflux in preterm and term infants with reflux disease. Gut 2002; 51 (04) 475-479
  • 13 López-Alonso M, Moya MJ, Cabo JA. , et al. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux. Pediatrics 2006; 118 (02) e299-e308
  • 14 Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154 (04) 514-520
  • 15 Ho T, Dukhovny D, Zupancic JA, Goldmann DA, Horbar JD, Pursley DM. Choosing wisely in newborn medicine: five opportunities to increase value. Pediatrics 2015; 136 (02) e482-e489
  • 16 Chen IL, Gao WY, Johnson AP. , et al. Proton pump inhibitor use in infants: FDA reviewer experience. J Pediatr Gastroenterol Nutr 2012; 54 (01) 8-14
  • 17 Rosen R, Vandenplas Y, Singendonk M. , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66 (03) 516-554
  • 18 Jadcherla SR, Slaughter JL, Stenger MR, Klebanoff M, Kelleher K, Gardner W. Practice variance, prevalence, and economic burden of premature infants diagnosed with GERD. Hosp Pediatr 2013; 3 (04) 335-341
  • 19 D'Agostino JA, Passarella M, Martin AE, Lorch SA. Use of gastroesophageal reflux medications in premature infants after NICU discharge. Pediatrics 2016; 138 (06) e20161977
  • 20 Kaguelidou F, Alberti C, Biran V. , et al. Dose-finding study of omeprazole on gastric pH in neonates with gastro-esophageal acid reflux using a Bayesian sequential approach. PLoS One 2016; 11 (12) e0166207
  • 21 Hyman PE, Clarke DD, Everett SL. , et al. Gastric acid secretory function in preterm infants. J Pediatr 1985; 106 (03) 467-471
  • 22 Akinola E, Rosenkrantz TS, Pappagallo M, McKay K, Hussain N. Gastroesophageal reflux in infants < 32 weeks gestational age at birth: lack of relationship to chronic lung disease. Am J Perinatol 2004; 21 (02) 57-62
  • 23 Finer NN, Higgins R, Kattwinkel J, Martin RJ. Summary proceedings from the apnea-of-prematurity group. Pediatrics 2006; 117 (3 Pt 2): S47-S51
  • 24 Khalaf MN, Porat R, Brodsky NL, Bhandari V. Clinical correlations in infants in the neonatal intensive care unit with varying severity of gastroesophageal reflux. J Pediatr Gastroenterol Nutr 2001; 32 (01) 45-49
  • 25 Schurr P, Findlater CK. Neonatal myth busters: evaluating the evidence for and against pharmacologic and nonpharmacologic management of gastroesophageal reflux. Neonatal Netw 2012; 31 (04) 229-241
  • 26 Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia 2009; 64 (06) 652-657